Stockscreener 앱 받기
5.81
7.04%
-0.44
전일 마감가:
$6.25
열려 있는:
$6.21
하루 거래량:
51,720
Relative Volume:
0.20
시가총액:
$6.30M
수익:
$72,100
순이익/손실:
$-4.84M
주가수익비율:
-0.7792
EPS:
-7.4566
순현금흐름:
$-3.84M
1주 성능:
-9.22%
1개월 성능:
-3.24%
6개월 성능:
-3.41%
1년 성능:
-35.87%
1일 변동 폭
$5.71
$6.285
1주일 범위
$5.71
$6.75
52주 변동 폭
$3.315
$15.15
Silo Pharma Inc Stock (SILO) Company Profile
명칭
Silo Pharma Inc
전화
(718) 400-9031
주소
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.33 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.79 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.25 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.77 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.74 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc 주식(SILO)의 최신 뉴스
SILO PHARMA INC (SILO) Stock Chart - ChartMill
SILO Q4 2023 Earnings: EPS Misses Estimates; Pre-Revenue Biotech Faces Cash Burn ConcernsEarnings Outlook Update - newsline.com
SILO Q4 2023 Earnings: EPS Misses Estimates as Company Advances PipelineDividend Cut Risk - newsline.com
Why Did SILO Stock Soar 85% Today? - Stocktwits
Silo Pharma Implements Reverse Stock Split and Restructures Capital - The Globe and Mail
Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split - Moomoo
Silo Pharma (SILO) completes 1-for-15 reverse stock split and cuts authorized shares - Stock Titan
Silo Pharma Announces 1-for-15 Reverse Stock Split - The Globe and Mail
Silo Pharma announces 1-for-15 reverse stock split effective June 2 - Investing.com UK
Silo Pharma announces 1-for-15 reverse stock split effective June 2 By Investing.com - Investing.com South Africa
Silo Pharma to implement 1-for-15 reverse stock split, issued shares fall to ~1.084M - TradingView
Reverse split shrinks Silo Pharma (NASDAQ: SILO) share count and authorization - Stock Titan
SILO Q4 2023 Earnings: EPS Misses Estimates as Development-Stage Biotech Maintains FocusWeak Earnings Momentum - The Legal Advocate
Silo Pharma Inc. (SILO) Holds Above $0.40 Support After Modest GainsShort Setup Alerts - newsline.com
Silo Pharma (SILO) Surges 5% as Small-Cap Biotech Recovers From Recent LowsSupply Zone - newsline.com
Silo Pharma Inc. (SILO) Rallies 3.99% as Biotech Sentiment Improves — Key Levels in FocusDebt Free Companies - The Legal Advocate
Silo Pharma Inc. (SILO) Q4 2023 Earnings: Widening Losses as Pre-Revenue Biotech Focuses on Pipeline ProgressProfit Margin Analysis - Newser
SILO Q4 2023 Earnings: Biotech Misses EPS Estimates as Pre‑Revenue Phase ContinuesCrowd Stock Picks - Newser
Silo Pharma Inc. (SILO) Edges Higher as Shares Test Key ResistanceAggressive Growth Picks - Newser
Silo Pharma (SILO) Q4 2023 Results Disappoint: What Investors Should KnowRevenue Miss Report - The Legal Advocate
Silo Pharma (SILO) Q4 2023 Earnings: Miss Sparks ConcernTrending Entry Points - Newser
Silo Pharma (SILO) Stock Analysis: Falls -3.79%, Watching $0.35 2026-05-19NHNL Ratio - The Legal Advocate
Silo Pharma (SILO) Q4 2023 Results Miss Estimates — EPS $-0.36 vs $-0.20Special Dividend Alert - newsline.com
Silo Pharma, Inc. (SILO) Q1 2026 10-Q: Financials, Crypto Asset Holdings, and Business Developments - Minichart
Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Silo Pharma (NASDAQ: SILO) Q1 loss widens as R&D and crypto costs rise - Stock Titan
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative - citybuzz -
Silo Pharma files patent for ibogaine-based TBI treatment By Investing.com - Investing.com Australia
Silo Pharma files patent for ibogaine-based TBI treatment - Investing.com
With no FDA-approved TBI drugs, Silo pursues ibogaine therapy - Stock Titan
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury - ChartMill
Silo Pharma rallies after securing key patent allowance - MSN
SILO Stock Price, Quote & Chart | SILO PHARMA INC (NASDAQ:SILO) - ChartMill
SILO Silo Pharma reports wider-than-expected Q4 2023 loss, shares dip 1.62% amid weak investor sentiment.High Attention Stocks - Newser
Silo Pharma’S Ptsd Program Advances As FDA Fast-Tracks Psychedelic Therapies For Ptsd - TradingView
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD - GlobeNewswire
Washington speeds psychedelic PTSD work as Silo spotlights program - Stock Titan
Why did SILO stock soar 85% today? - MSN
Levi Strauss, Greenbrier and 3 stocks to watch heading into Tuesday - MSN
SILO Silo Pharma rises 5.57 percent despite reporting a wider than expected Q4 2023 per share loss.Gross Margin - Newser
CMND stock set for biggest intraday gains in over three years — here’s why retail is eyeing further upside - MSN
SILO Price Today: Silo Pharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
12 Health Care Stocks Moving In Thursday's Pre-Market SessionAxe Compute (NASDAQ:AGPU), Akanda (NASDAQ - Benzinga
Silo Pharma Inc (SILO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Silo Pharma Inc 주식 (SILO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
2.60%
0.94%
자본화:
|
볼륨(24시간):